Hydroxychloroquine (Plaquenil)

Hydroxychloroquine (Plaquenil) is an anti-malarial medication used for a variety of inflammatory diseases including systemic lupus erythematosus as well as rheumatoid arthritis and Sjogren's Syndrome. Long term use of hydroxychloroquine is contraindicated for Marshall Protocol patients for several reasons.

Hydroxychloroquine may be ineffective and dangerous

There are several reasons why use of hydroxychloroquine is advised against.

If using Hydroxychloroquine during the COVID-19 epidemic, it seems the earlier the treatment is begun, the better the outcome.

Weaning from hydroxychloroquine

Plaquenil lingers in the system at least 50 days and cannot be taken long term while on the MP. Dr. Blaney reports he starts his patients on Benicar while they are waiting for Plaquenil to clear their system and has seen no adverse events. He prefers to wait a couple months before starting minocycline.

Trevor Marshall, PhD

===== Notes and comments =====

===== References =====

Flach AJ. Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine. Trans Am Ophthalmol Soc. 2007;105:191-4; discussion 195-7.
[PMID: 18427609] [PMCID: 2258132]
Abdel-Hamid H, Oddis CV, Lacomis D. Severe hydroxychloroquine myopathy. Muscle Nerve. 2008 Sep;38(3):1206-10. doi: 10.1002/mus.21091.
[PMID: 18720511] [DOI: 10.1002/mus.21091]
home/othertreatments/antibacterials/plaquenil.txt · Last modified: 09.14.2022 by
© 2015, Autoimmunity Research Foundation. All Rights Reserved.